Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019

Ma, Shaodi; Guo, Cijuan; Sun, Chenyu; Han, Tiantian; Zhang, Huimei; Qu, Guangbo; Jiang, Yuemeng; Zhou, Qin; Sun, Yehuan

doi:10.1016/j.clbc.2021.02.005

Cited by 42 publications

(23 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional systemic evidence of chronic inflammatory changes associated with breast cancer is provided by studies of the anti-inflammatory agent aspirin (ASA). When taken regularly, ASA has been shown to reduce the risk for breast cancer in women [17]. A recent meta-analysis suggested that aspirin may reduce the overall risk of breast cancer, reduce the risk of breast cancer in postmenopausal women, hormone-receptor-positive tumors, and in situ breast cancer [17].…”

Section: Evidence Of Inflammation Associated With Breast Cancer Riskmentioning

confidence: 99%

“…When taken regularly, ASA has been shown to reduce the risk for breast cancer in women [17]. A recent meta-analysis suggested that aspirin may reduce the overall risk of breast cancer, reduce the risk of breast cancer in postmenopausal women, hormone-receptor-positive tumors, and in situ breast cancer [17]. Bertrand et al [18] also reported a benefit of aspirin in ER negative and triple negative breast cancer in African American women.…”

Section: Evidence Of Inflammation Associated With Breast Cancer Riskmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Chronic Inflammation in the Development of Breast Cancer

Danforth

2021

Cancers

View full text Add to dashboard Cite

Chronic inflammation contributes to the malignant transformation of several malignancies and is an important component of breast cancer. The role of chronic inflammation in the initiation and development of breast cancer from normal breast tissue, however, is unclear and needs to be clarified. A review of the literature was conducted to define the chronic inflammatory processes in normal breast tissue at risk for breast cancer and in breast cancer, including the role of lymphocyte and macrophage infiltrates, chronic active adipocytes and fibroblasts, and processes that may promote chronic inflammation including the microbiome and factors related to genomic abnormalities and cellular injury. The findings indicate that in healthy normal breast tissue there is systemic evidence to suggest inflammatory changes are present and associated with breast cancer risk, and adipocytes and crown-like structures in normal breast tissue may be associated with chronic inflammatory changes. The microbiome, genomic abnormalities, and cellular changes are present in healthy normal breast tissue, with the potential to elicit inflammatory changes, while infiltrating lymphocytes are uncommon in these tissues. Chronic inflammatory changes occur prominently in breast cancer tissues, with important contributions from tumor-infiltrating lymphocytes and tumor-associated macrophages, cancer-associated adipocytes and crown-like structures, and cancer-associated fibroblasts, while the microbiome and DNA damage may serve to promote inflammatory events. Together, these findings suggest that chronic inflammation may play a role in influencing the initiation, development and conduct of breast cancer, although several chronic inflammatory processes in breast tissue may occur later in breast carcinogenesis.

show abstract

Section: Evidence Of Inflammation Associated With Breast Cancer Riskmentioning

confidence: 99%

Section: Evidence Of Inflammation Associated With Breast Cancer Riskmentioning

confidence: 99%

The Role of Chronic Inflammation in the Development of Breast Cancer

Danforth

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Additionally, regular use of NSAIDs could reduce BC risk [ 30 ]. Among different NSAIDs, frequent use of aspirin could be more effective in reducing the risk of BC [ 31 – 33 ]. In addition to the results of our study, there is a line of evidence that NSAIDs (including aspirin and ibuprofen) could significantly decrease circulating estradiol levels in postmenopausal women, followed by protection against BC [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Aspirin versus placebo on estrogen levels in postmenopausal women: a double-blind randomized controlled clinical trial

Oghazian

Shirzad

Ahadi

et al. 2022

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background Estrogen is involved in the pathogenesis of breast and gynecological cancers. Regular use of aspirin reduces estrogen levels. The present study aimed to evaluate the effect of aspirin on estrogen levels in postmenopausal women. Methods This double-blind, placebo-controlled parallel-group trial was conducted on postmenopausal women referred to an outpatient clinic at a women’s hospital in Tehran. Volunteers were randomly assigned to receive aspirin 100 mg/day or placebo for 6 weeks. Estradiol, sex hormone-binding globulin (SHBG), and testosterone levels at baseline and at the end of the intervention were measured by ELISA. Data were analyzed using SPSS 20, Kolmogorov–Smirnov test, independent samples t-test, and Mann–Whitney U test. Results Twenty-seven and 28 participants were finally analyzed in the aspirin and placebo groups, respectively. There was no significant difference between the two groups in body mass index (BMI), age, or menopausal years. There was a statistically significant difference (p = 0.002) in the amount of change in estradiol levels of the intervention group (median=− 3.5 pg/ml) compared to the control group (median=1.5 pg/ml). In contrast, there were no significant differences between the two groups regarding testosterone and SHBG levels (p = 0.58, p = 0.32). Conclusions Since low doses of aspirin may decrease estradiol levels, it could be considered a promising adjunctive therapeutic candidate in postmenopausal women to decrease BC incidence. However, further studies with larger sample sizes, measurements of estrogen levels and its related compounds in different time points accompanied by long-term follow-ups are needed to better elucidate the potential mechanisms by which nonsteroidal anti-inflammatory drugs (NSAIDs) negatively affect breast cancer. Trial registration IRCT201012195397N1. Date of first registration: 03/01/2011.

show abstract

“…The ReDO_Trials Database lists 39 active trials, (as of 14 December 2021) that include aspirin in a treatment arm. In terms of cancer prevention, there are numerous retrospective studies showing positive effects, particularly in colorectal cancer [ 94 , 95 ], but also in breast [ 96 ], liver [ 97 ] and some other cancers. There are also some data suggesting beneficial effects of aspirin post-diagnosis in colorectal and breast cancer [ 98 , 99 ].…”

Section: Drugging the Undruggablementioning

confidence: 99%

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Pantziarka

Blagden

2022

Cancers

View full text Add to dashboard Cite

The concept of the pre-cancerous niche applies the ‘seed and soil’ theory of metastasis to the initial process of carcinogenesis. TP53 is at the nexus of this process and, in the context of Li-Fraumeni Syndrome (LFS), is a key determinant of the conditions in which cancers are formed and progress. Important factors in the creation of the pre-cancerous niche include disrupted tissue homeostasis, cellular metabolism and chronic inflammation. While druggability of TP53 remains a challenge, there is evidence that drug re-purposing may be able to address aspects of pre-cancerous niche formation and thereby reduce the risk of cancer in individuals with LFS.

show abstract

Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019

Cited by 42 publications

References 57 publications

The Role of Chronic Inflammation in the Development of Breast Cancer

The Role of Chronic Inflammation in the Development of Breast Cancer

Aspirin versus placebo on estrogen levels in postmenopausal women: a double-blind randomized controlled clinical trial

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Contact Info

Product

Resources

About